Announcing the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer
Isotopia to supply POINT with no-carrier-added Lu-177 for use in POINT’s Indianapolis, IN radioligand production facility
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”. Gross proceeds from the transaction totaled approximately $286.7 million.
POINT announced today the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs ...
POINT today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy.